FDA issues new safety alert on Reumofan Plus and Reumofan Plus Premium
date:Aug 22, 2012
act with other medications and result in serious adverse events. Health care professionals are urged to ask their patients about use of Reumofan Plus, Reumofan Plus Premium, and other similar products marketed as dietary supplements when patients present with unexplained symptoms that suggest NSAID toxicity, psychiatric changes, or the use or abrupt discontinuation of corticosteroids.

Additionally, health care professionals should evaluate patients who have used Reumofan Plus and/or Reumofan Pl
6/7 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/02 01:58